Joint Co.

The Joint reported adjusted EPS of $0.05 for Q2 2026 (expectation $0.03) and revenue of $15.2m (+14% y/y), with both metrics topping estimates. Adjusted EBITDA from continuing operations rose to $1.5m, and free cash flow and operating cash flows improved markedly. However, systemwide sales and comparable sales declined, and the company lowered its clinic-opening target to 22–26 locations. The group affirms most of its full-year outlook and continues to view the shift to a capital-conserving franchise model as a driver of higher margins. » Plus sur de.investing.com

The Joint Corp. elected Milind Pant to its board following the annual general meeting, expanding the board to seven members. Pant is founder and CEO of Karyon Leadership Advisory, serves on the board of The Western Union Company and was previously CEO of Amway Corporation as well as holding leadership roles at Yum! Brands and Unilever. The franchise operator of chiropractic clinics runs more than 940 locations; the stock is valued at around $119 million and is trading below fair value according to InvestingPro, while management has recently been aggressively buying back shares. » Plus sur de.investing.com

The Joint Corp. reported Q1 2026 EPS of $0.08, beating analysts' estimate of $0.04; revenue rose 13% year‑over‑year to $14.8 million. Adjusted EBITDA from continuing operations climbed sharply to $2.2 million, and net income turned positive. Despite the stronger numbers, the stock fell 1.48% after hours, weighed down by macroeconomic headwinds and declining systemwide sales. Management emphasizes the shift to a pure franchisor model and expects EPS of $0.05 and $0.07 for Q2 and Q3 and revenue guidance of $14.35 million and $14.69 million, respectively. » Plus sur de.investing.com